Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.49 |
| ▸ | MALT1 | Q9UDY8 | 5/20 | 0.43 |
| ▸ | ULK1 | O75385 | 6/20 | 0.39 |
| ▸ | ULK2 | Q8IYT8 | 2/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | HTT | P42858 | 3/20 | 0.35 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3141402 | 0.94 | TLR7 (0.51) | TLR7MALT1ULK1LMNAHTT | |
| SCHEMBL26125024 | 0.80 | LMNA (0.38) | ULK1ULK2IRAK4LMNAHTT | |
| SCHEMBL3255130 | 0.78 | PDE4A (0.51) | TLR7ULK1 | |
| SCHEMBL29623553 | 0.78 | PDE4A (0.51) | TLR7ULK1 | |
| SCHEMBL3133575 | 0.78 | ADORA3 (0.50) | TLR7LMNAHTTPAK1PKM | |
| SCHEMBL7111201 | 0.77 | ADORA3 (0.41) | LMNAHTTPAK1PKMHSD17B10 | |
| SCHEMBL16146711 | 0.77 | LRRK2 (0.39) | IRAK4LMNAHTTPAK1PKM | |
| SCHEMBL133156 | 0.77 | CHUK (0.45) | LMNAHTTPAK1PKMHSD17B10 | |
| SCHEMBL16146849 | 0.77 | LMNA (0.38) | IRAK4LMNAHTTPAK1PKM | |
| SCHEMBL30590050 | 0.77 | CHUK (0.45) | LMNAHTTPAK1PKMHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100010020-A1 | PHOSPHODIESTERASE 4 INHIBITORS | LIU RUIPING | 2010-01-14 | — | — | US | disclosed |
| US-20100004236-A1 | PHOSPHODIESTERASE 4 INHIBITORS | TEHIM ASHOK | 2010-01-07 | — | — | US | disclosed |
| EP-1529049-B1 | DERIVATIVES OF 2-TRIFLUORMETHYL-6-AMINOPURINE AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARM CORP (US) | 2009-11-18 | — | — | EP | disclosed |
| US-20080139583-A1 | PHOSPHODIESTERASE 4 INHIBITORS | TEHIM ASHOK | 2008-06-12 | — | — | US | disclosed |
| US-20080119495-A1 | PHOSPHODIESTERASE 4 INHIBITORS | LIU RUIPING | 2008-05-22 | — | — | US | disclosed |
| US-7342021-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. (US) | 2008-03-11 | — | — | US | disclosed |
| US-7332486-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. (US) | 2008-02-19 | — | — | US | disclosed |
| US-20070093510-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. (US) | 2007-04-26 | — | — | US | disclosed |
| EP-1529049-A2 | DERIVATIVES OF 2-TRIFLUORMETHYL-6-AMINOPURINE AS PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceutical Corporation (US) | 2005-05-11 | — | — | EP | disclosed |
| US-20040242598-A1 | Phosphodiesterase 4 inhibitors | LIU RUIPING (US) | 2004-12-02 | — | — | US | disclosed |
| WO-2004014913-A2 | DERIVATIVES OF 2-TRIFLUORMETHYL-6-AMINOPURINE AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2004-02-19 | — | — | WO | disclosed |
| EP-1383767-A1 | TRIFLUOROMETHYLPURINES AS PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceutical Corporation (US) | 2004-01-28 | — | — | EP | disclosed |
| US-20030045533-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. | 2003-03-06 | — | — | US | disclosed |
| WO-2002098878-A1 | TRIFLUOROMETHYLPURINES AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093510-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE3B, PDE3A | TLR7 4771/4885MALT1 4725/4885ULK1 4781/4885 |
| US-20080139583-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE3B, PDE3A | TLR7 4771/4885MALT1 4725/4885ULK1 4781/4885 |
| US-20030045533-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE3A, PDE3B | TLR7 4751/4885MALT1 3780/4885ULK1 4775/4885 |
| US-20100004236-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE3B, PDE3A | TLR7 4771/4885MALT1 4725/4885ULK1 4781/4885 |
| US-20040242598-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE3A, PDE3B | TLR7 4751/4885MALT1 3780/4885ULK1 4775/4885 |
| US-20080119495-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE3B, PDE3A | TLR7 4771/4885MALT1 4725/4885ULK1 4781/4885 |
| US-20100010020-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE3B, PDE3A | TLR7 4771/4885MALT1 4725/4885ULK1 4781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.